tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Sean Laaman, 2 are a HOLD (18.18%), 9 are a BUY (81.82%).
Analyst Sean Laaman, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 42.86% that have a potential upside of 6.44% achieved within 37 days.
Sean Laaman’s has documented 21 price targets and ratings displayed on 2 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on EXEL, Exelixis at 21-Oct-2025.
Analyst best performing recommendations are on RMD (RESMED).
The best stock recommendation documented was for RMD (RESMED) at 6/17/2020. The price target of $176 was fulfilled within 8 days with a profit of $11.06 (6.71%) receiving and performance score of 8.38.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$300
$53.12 (21.52%)
$270
2 days ago
(31-Oct-2025)
14/15 (93.33%)
$53.12 (21.52%)
98
Buy
$304
$57.12 (23.14%)
$219
12 days ago
(21-Oct-2025)
6/7 (85.71%)
$35.78 (13.34%)
73
Buy
$330
$83.12 (33.67%)
$285
1 months 15 days ago
(18-Sep-2025)
7/8 (87.5%)
$56.71 (20.75%)
38
Buy
$290
$43.12 (17.47%)
6 months 9 days ago
(24-Apr-2025)
17/17 (100%)
$54.9 (23.35%)
363
Hold
$248
$1.12 (0.45%)
$260
6 months 9 days ago
(24-Apr-2025)
3/3 (100%)
$12.9 (5.49%)
70
Which stock is Sean Laaman is most bullish on?
Which stock is Sean Laaman is most reserved on?
What Year was the first public recommendation made by Sean Laaman?
